Toronto – – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) replaced its chief financial officer effective immediately, promoting Corporate Controller Matthew Sobczyk to Interim CFO after Rashed Dewan stepped down from the role.

Sobczyk, a 2020 hire, takes over the finance function

Sobczyk first joined the interventional MRI (iMRI) company in 2020 and moves up from Corporate Controller. The company did not name a permanent successor or give a timeline for a CFO search.

Dewan stays on a short-term consulting contract

Dewan will remain with Profound under a short-term consulting contract to support the handover. CEO and Chairman Arun Menawat thanked him for his years of service and his contributions to the company.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has introduced new Treatment Delivery Console (TDC) software that it says provides a roadmap for surgeons to perform up to six TULSA Procedures per system per day, up from a reported maximum of four among a few physicians today.

Software rolls out across the TULSA-PRO installed base

The update is being deployed across Profound's TULSA-PRO installed base. It builds on earlier TULSA-AI modules aimed at raising procedural efficiency, improving physician experience and reducing planning complexity.

The release adds two feature sets. The first is real-time interventional MRI (iMRI) control. The second is a package of physician-requested improvements to the user interface and hardware control. Profound says both are designed to further increase TULSA Procedure efficiency and support regional ablation of tissue for a variety of prostate indications.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has appointed Richard Fabian, a medical imaging executive with more than 29 years of experience, as President, effective immediately, as the company moves its previous President into a newly created Chief Technology Officer role.

Fabian succeeds Mathieu Burtnyk, who becomes Chief Technology Officer

Fabian replaces Mathieu Burtnyk, PhD, who shifts to the newly created CTO position. Burtnyk invented the patented closed-loop temperature feedback control algorithm used by the TULSA-PRO platform. He has also led the scientific design and execution of all of the company's clinical studies for the technology, including the ongoing Level 1 post-market CAPTAIN randomized controlled trial.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) will hold one-on-one investor meetings at the Lake Street Capital Markets "BIG10" Conference in New York City on September 10, 2026.

The event runs in a one-on-one meeting format only. Profound will not offer a webcast, so investors who want access to management must attend the meetings in person.

Profound Medical sells interventional MRI therapies built around two platforms

The commercial-stage medical device company develops and markets interventional MRI (iMRI) procedures. Its flagship platform, TULSA-PRO, enables MRI-guided, incision-free prostate ablation. Physicians use the TULSA Procedure to see, ablate and confirm therapy in real time. The approach covers treatment from whole-gland to subtotal, hemi, multifocal and focal ablation.

Toronto – October 12, 2026 -- Profound Medical Corp. expects third-quarter 2026 revenue of $9.8 million to $10.0 million, roughly 45% to 47% above the Bloomberg mean analyst consensus of $6.78 million.

Revenue nearly doubles year over year and almost quadruples sequentially

The preliminary, unaudited range implies growth of approximately 85% to 89% from $5.3 million in the third quarter of 2025. Compared with $2.5 million in the second quarter of 2026, revenue is expected to rise approximately 292% to 300%.

The Nasdaq- and TSX-listed company expects gross margin to exceed 70% for the quarter, again above that threshold. Profound attributes the margin to progress in its commercial operations and scale.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has signed a co-education agreement with Telix Pharmaceuticals Limited (ASX:TLX; NASDAQ:TLX), giving it wider access to urologists in the U.S. and internationally through a strategic partner in prostate cancer imaging.

The agreement sets a framework to educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on how Telix's PSMA-targeting PET imaging agents, Gozellix and Illuccix, complement Profound's MRI-guided TULSA-PRO platform. The companies plan to cover the full prostate care continuum.

Madrid – October 12, 2026 -- Getnet, Santander's global merchant payments platform, now gives multinational merchants, marketplaces and e-commerce companies access to payment services in more than 30 European countries through a single integration.

The launch extends Getnet's footprint beyond Latin America, Spain and Portugal. It targets merchants that must handle multiple payment methods, regulations and technical integrations as European commerce becomes more cross-border.

Getnet Single Entry Point connects merchants to multiple markets through one integration

The infrastructure, called Getnet Single Entry Point (SEP), also provides access to leading local payment methods. These include Bizum in Spain and MB WAY in Portugal, where Getnet operates as a direct member.

Dublin – – October 12, 2026 -- AerCap Holdings N.V. (NYSE: AER) has signed lease agreements with China Southern Air Logistics Co. Ltd. (China Southern Airlines Cargo) for three Boeing 777-300ERSF converted freighters, with the first delivery set for October 2027.

Deliveries run from October 2027 to Q2 2028

The second aircraft is scheduled for delivery in Q1 2028 and the third in Q2 2028. The 777-300ERSF, known as "The Big Twin," is the first passenger-to-freighter conversion program for the Boeing 777-300ER. The aircraft is powered by the GE90 platform.

China Southern targets intercontinental route growth

Li Xiao, Chairman of CSA Logistics, said the aircraft support the carrier's strategy to expand intercontinental routes. He called the introduction of the type "a major milestone in the continued evolution of our fleet."

Farnborough – October 12, 2026 -- AerCap Holdings N.V. (NYSE: AER) placed a direct order for 15 Boeing 787-9 Dreamliners, taking its fleet of 787 aircraft to approximately 140. The lessor announced the order at the 2026 Farnborough International Air Show.

AerCap schedules deliveries of the 15 aircraft through 2033

The aircraft will be delivered through 2033, giving the lessor a long-dated widebody pipeline. AerCap selected GE Aerospace's GEnx-1B engines to power all 15 jets.

Order includes substitution rights to the larger 787-10

The agreement lets AerCap switch from the 787-9 to the larger 787-10 variant. The company said the option gives it flexibility as it works to meet the changing needs of its customers.

Dublin – October 12, 2026 -- AerCap Holdings N.V. raised its full-year 2026 adjusted earnings per share guidance to approximately $16.80 after reporting second-quarter net income of $726 million, or $4.59 per share. Adjusted net income reached $811 million, or $5.14 per share. The guidance excludes any additional gains on sale for the rest of the year.

AerCap sells $1.4 billion of assets at a 20% unlevered gain margin

The lessor booked a net gain on sale of $223 million on 38 owned assets sold for $1.4 billion. A year earlier it recorded $57 million of gains on 18 assets sold for $374 million. The second-quarter sales equate to 1.7x book value on an equity basis.

Return on equity was 16% for the quarter, or 18% on an adjusted basis. Operating cash flow totaled $1.5 billion.